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Summary
Inactivation of the TSC2 tumor suppressor protein causes tuberous sclerosis complex (TSC), a disease characterized by
highly vascular tumors. TSC2 has multiple functions including inhibition of mTOR (mammalian target of Rapamycin). We
found that TSC2 regulates VEGF through mTOR-dependent and -independent pathways. TSC2 loss results in the accumula-
tion of HIF-1 and increased expression of HIF-responsive genes including VEGF. Wild-type TSC2, but not a disease-
associated TSC2 mutant, downregulates HIF. Rapamycin normalizes HIF levels in TSC2/ cells, indicating that TSC2
regulates HIF by inhibiting mTOR. In contrast, Rapamycin only partially downregulates VEGF in this setting, implying an
mTOR-independent link between TSC2 loss and VEGF. This pathway may involve chromatin remodeling since the HDAC
inhibitor Trichostatin A downregulates VEGF in TSC2/ cells.
Introduction lian target of Rapamycin). In the presence of serum, AKT is
activated and phosphorylates TSC2, which disrupts TSC2 bind-
ing to TSC1 (Dan et al., 2002; Gao and Pan, 2001; Inoki et al.,Tuberous sclerosis complex (TSC; depending on the context,
the term “TSC” will be used to refer to the disease tuberous 2002; Manning et al., 2002; Potter et al., 2002; Radimerski et
al., 2002). Dissolution of the TSC2/TSC1 complex allows forsclerosis complex or as a generic designation for the TSC1 and
TSC2 proteins) is a disease characterized by the development activation of mTOR, which phosphorylates 4E-BP and S6 kinase
(Tee et al., 2002), ultimately leading to an increase in the ratesof benign tumors, called hamartomas, in multiple tissues includ-
ing the skin, central nervous system, lung, heart, and kidneys. of protein translation (Gingras et al., 2001). Treatment with Rapa-
mycin, a specific mTOR inhibitor, results in the accumulationThese tumors are composed of multiple cell types and are fre-
quently highly vascular. TSC patients also appear to be at in- of unphosphorylated S6, inhibition of translation, and cell cycle
arrest.creased risk for malignant renal carcinomas (RCC) of clear cell
histology (Iliopoulos and Eng, 2000). TSC affects approximately Notably, the mTOR pathway is activated in tumors from
TSC patients (Goncharova et al., 2002; Kenerson et al., 2002).1 in 6000 live births and is linked to germline inactivating muta-
tions of either of two genes, TSC1 or TSC2, with each gene However, whether inhibition of mTOR fully accounts for the
tumor suppressor activities of TSC2 (and TSC1) is unclear (Mo-accounting for approximately 50% of the cases (Cheadle et al.,
2000). mose et al., 2002). TSC2 also functions as a GAP toward the
small G protein Rheb, which acts upstream of mTOR (GaramiTSC2 encodes a protein of 200 kDa, TSC2 (also called Tu-
berin), which is ubiquitously expressed and localizes to the et al., 2003; Saucedo et al., 2003; Stocker et al., 2003). This
activity is probably important for TSC function because theperinuclear Golgi (The European Chromosome 16 Tuberous
Sclerosis Consortium, 1993; Wienecke et al., 1996). TSC2 does TSC2 GAP domain, and the surrounding region, are particularly
well conserved in orthologous proteins in Drosophila andnot closely resemble other human proteins. TSC2 forms a com-
plex with TSC1 that functions to integrate growth factor signals C. elegans, and inactivation of Rheb restores the viability of
Tsc-defective Drosophila larvae. Moreover, the GAP domainwith the cell growth regulatory apparatus (Marygold and Lee-
vers, 2002). This complex negatively regulates mTOR (mamma- is important for TSC2-dependent tumor suppression in vivo
S I G N I F I C A N C E
Tuberous sclerosis complex (TSC) is a hereditary cancer syndrome caused by mutations in either of two tumor suppressor genes,
TSC1 or TSC2. We found that TSC2, by virtue of its known ability to inhibit mTOR, downregulates the HIF transcription factor. This may
explain the phenotypic similarities between TSC and von Hippel-Lindau disease, which is also characterized by excessive HIF. HIF
activates a variety of genes implicated in tumorigenesis, including VEGF. VEGF overproduction by TSC2/ cells was only partially
inhibited by the mTOR antagonist Rapamycin, implying an additional, mTOR-independent link between TSC2 and VEGF. The HDAC
inhibitor Trichostatin A downregulates VEGF production in TSC2-defective cells, suggesting that mTOR inhibitors and HDAC inhibitors
might be beneficial for the treatment of TSC.
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(Momose et al., 2002). While expression of a wild-type TSC2 upregulation (Jiang et al., 2001; Laughner et al., 2001; Treins
et al., 2002; Zelzer et al., 1998; Zhong et al., 2000; Zundel etcDNA transgene in the Eker rat, which is a naturally occurring
model of TSC caused by an inactivating mutation in Tsc2, sup- al., 2000). HIF upregulation can be blocked by inhibitors of PI3K
and to a lesser extent inhibitors of mTOR, but the generalizabilitypresses tumor formation, a TSC2 deletion mutant lacking the
GAP domain does not (Momose et al., 2002). of these findings has been questioned (Alvarez-Tejado et al.,
2002; Arsham et al., 2002).Eker rats develop a variety of tumors including RCC and
splenic hemangiosarcomas (Eker et al., 1981; Yeung et al., Here we show that TSC2 regulates VEGF through both
mTOR-dependent and -independent pathways. TSC2 loss re-1994). In the mouse, heterozygous mutations in Tsc2, or Tsc1,
result in liver hemangiomas as well as kidney cystic lesions, sults in the accumulation of HIF-1 (particularly under conditions
of low serum and prolonged hypoxia) and increased expressionwhich occasionally harbor features of malignancy (Kobayashi
et al., 1999, 2001; Kwiatkowski et al., 2002; Onda et al., 1999). of HIF-responsive genes. Interestingly, the levels of VEGF mRNA
are upregulated disproportionately to other HIF-responsive tran-Homozygous inactivation of either Tsc2 or Tsc1 causes embry-
onic lethality. scripts. Reconstitution with wild-type TSC2, but not a disease-
associated mutant, downregulates HIF-1. HIF-1 upregulationWhile the tumor spectrum of patients with TSC and that of
the animal models is quite different, a common feature is their associated with TSC2 inactivation is linked to mTOR function
and can be inhibited by Rapamycin. Notably, while Rapamycinvascular nature. TSC patients develop cutaneous angiofibromas
and renal angiomyolipomas, which are highly vascular. The ro- treatment of TSC2-null cells normalizes the levels of the HIF-1
and the HIF-regulated protein GLUT-1, Rapamycin only partiallydents develop RCC, hemangiomas, and hemangiosarcomas.
This observation suggests that TSC plays a role in the regulation downregulates VEGF. These results strongly suggest the exis-
tence of an mTOR-independent mechanism of VEGF regulationof angiogenesis. In support of this idea, immunohistochemical
analysis of cutaneous angiofibromas from TSC patients reveals by TSC2. Importantly, VEGF can be effectively downregulated
in TSC2-null cells by the HDAC inhibitor Trichostatin A, but notincreased production of angiogenic factors including basic fi-
broblast growth factor (bFGF), platelet-derived endothelial cell by a number of other inhibitors of pathways known to regulate
VEGF. These results suggest that loss of TSC2 may ultimatelygrowth factor (PD-ECGF), angiogenin, and VEGF (Nguyen-Vu
et al., 2001). In addition, the conditioned media of Tsc2-null increase VEGF levels through alterations in chromatin structure.
fibroblasts from the Eker rat stimulates endothelial cell prolifera-
tion to a greater extent than that of wild-type controls (Nguyen- Results
Vu et al., 2001).
Interestingly, animal models of TSC develop phenotypes Tsc2-null cells exhibit increased levels of Hif-1
To determine the effects of Tsc2 loss on Hif, we analyzed mousethat are characteristic of Von-Hippel Lindau (VHL) disease in
humans. VHL disease, which results from inactivation of the embryo fibroblasts (MEFs) derived from Tsc2/ and Tsc2/
embryos. Loss of Tsc2 results in lethality during early embryonicVHL tumor suppressor gene, is characterized by highly vascular
tumors including RCC (which are often preceded by renal cysts) development when it is difficult to obtain large numbers of viable
fibroblasts (Kobayashi et al., 1999; Onda et al., 1999; Rennebeckand hemangiomas (Maher and Kaelin, 1997). These tumor types
are typical of animal models of TSC. Moreover, both Tsc2/ et al., 1998). To address this problem, Kwiatkowski and colleagues
crossed Tsc2/ mice with p53/ mice to generate MEFs that(or Tsc1/) and Vhl/ mice (Haase et al., 2001) develop liver
hemangiomas. These data suggest that the products of the TSC were also deficient for p53, which enhances the lifespan of the
limited number of MEFs that can be obtained (Onda et al.,and VHL genes are functionally related.
pVHL is a component of an E3 ubiquitin ligase complex that 1999). In the experiments that follow, Tsc2/;p53/ MEFs were
compared to Tsc2/;p53/ MEFs. For simplicity, these MEFstargets hypoxia-inducible factor (HIF) for degradation (Maxwell
et al., 1999). HIF is the generic name for the basic helix-loop- are referred to as “Tsc2/” and “Tsc2/,” respectively.
As shown in Figure 1A, Hif-1 protein levels were modestlyhelix heterodimeric transcription factor formed upon binding of
a HIF (HIF-1, -2, and -3) subunit to a HIF subunit (Kaelin, elevated in Tsc2/ cells compared to Tsc2/ cells (see also
Figures 1B and 1C). Treatment with the hypoxia mimetic Defer-2002). In contrast to the  subunit, which is stable and present
in the cell in vast excess, the  subunits are labile and highly oxamine (DFO) resulted in Hif-1 upregulation in both cell types
(Figure 1A). Induction of Hif-1 under hypoxic conditions (1%regulated. In the presence of oxygen, HIF is hydroxylated by
EGLN at specific Prolyl residues creating a high-affinity binding O2) was more pronounced in Tsc2-null cells compared to
Tsc2/ cells, with respect to both magnitude and durationsite for pVHL (Epstein et al., 2001; Ivan et al., 2001; Jaakkola
et al., 2001; Masson et al., 2001; Yu et al., 2001). Once bound, (Figure 1B). These data indicate that Tsc2 is required for proper
downregulation of Hif-1 levels following prolonged exposurepVHL directs the polyubiquitylation, and hence proteasomal
degradation, of HIF. Under hypoxic conditions, EGLN activity to hypoxia.
is diminished, which allows for the accumulation of unmodified
HIF. HIF, once bound to HIF, transcriptionally activates a Tsc2-null cells fail to downregulate Hif-1 in low serum
In the absence of growth factors, TSC2 inhibits mTOR leadingvariety of genes involved in acute or chronic adaptation to hy-
poxia. Among these are genes linked to angiogenesis such as to the accumulation of unphosphorylated S6. To begin to deter-
mine whether HIF-1 is regulated by TSC2 through mTOR, weVEGF (vascular endothelial growth factor) and PDGF B (platelet-
derived growth factor B). Accordingly, pVHL-defective tumor examined the effects of serum on Hif-1 protein levels. As ex-
pected, growth of Tsc2/ MEFs in low (0.5%) serum led tocells overexpress HIF target genes and are highly angiogenic.
In addition to pVHL, HIF is also regulated by the PI3K path- decreased S6 phosphorylation (Figure 1C). Incidentally, S6 pro-
tein levels also decreased under these conditions. Importantly,way. Activation of the PI3K pathway, through growth factor
stimulation or deletion of the PI3K inhibitor PTEN, results in HIF Hif-1 protein levels were also diminished in Tsc2/ cells when
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quently switched to low serum for 18 hr prior to analysis.
Both the wild-type and mutant TSC2 proteins were produced
at comparable levels and approximated the endogenous Tsc2
levels seen in untransfected Tsc2/ MEFs (Figures 2A and 2B).
Reconstitution with wild-type, but not mutant, TSC2 blocked S6
phosphorylation (data not shown) and markedly downregulated
Hif-1 protein levels (Figure 2A). The slight decrease in Hif-1
protein levels in the cells reconstituted with mutant TSC2 might
indicate that this particular missense mutant is not a true-null.
Nonetheless, impaired downregulation of Hif-1 by a disease-
associated TSC2 mutant is consistent with the idea that dysreg-
ulation of HIF contributes to tumor formation following TSC
inactivation.
Downregulation of TSC2 is sufficient
for HIF-1 upregulation
To determine whether Tsc2 downregulation is sufficient to
upregulate Hif-1, we performed knockdown experiments using
siRNA directed against TSC2 or, as a positive control, against
the HIF prolyl hydroxylase EGLN1 (Kaelin, 2002). Two different
TSC2 synthetic siRNAs were utilized that, in contrast to the
EGLN1 siRNA or a scrambled siRNA, markedly reduced TSC2
protein levels when introduced into U2OS osteosarcoma cells
(Figure 3A). As expected, EGLN1 siRNA increased HIF-1 levels,
especially in the absence of serum. Cells treated with either of
the two TSC2 siRNAs, but not the scrambled siRNA, accumu-
lated HIF-1 in the absence of serum (Figure 3B). Collectively,
these results indicate that TSC2 loss is both necessary and
sufficient for HIF-1 upregulation under conditions of serum
deprivation.
Hif-1 upregulation in Tsc2-null cells
Figure 1. Effect of Tsc2 loss on Hif-1
requires mTOR activity
A and B: Anti-Hif1 and anti-tubulin immunoblot analysis of Tsc2/ and To ask whether regulation of Hif-1 by TSC2 is mediated byTsc2/ cells. In A, cells were treated with DFO (200 M) for 10 hr where
mTOR, we evaluated the effects of Rapamycin on Hif-1 proteinindicated by “.” In B, cells were exposed to 1% oxygen for the duration
levels. As shown in Figure 4A, Rapamycin treatment inhibitsindicated prior to analysis.
C: Immunoblot analysis with the indicated antibodies of Tsc2/ and Tsc2/ S6 phosphorylation independently of Tsc2 status. Treatment of
cells grown in high (10%) or low (0.5%) serum. S6-P refers to an antibody Tsc2/ cells with Rapamycin had no appreciable effect on
recognizing S6 phosphorylated on Ser 235/236.
Hif-1 protein levels under both serum-rich and serum-poorD: Hif-1 Northern blot analysis of Tsc2/ and Tsc2/ cells grown in high
conditions (Figure 4B). In contrast, Rapamycin treatment de-(10%) or low (0.1%) serum.
creased Hif-1 levels in Tsc2/ cells under both serum-rich and
serum-poor conditions, resulting in a Hif-1 profile resembling
that observed in Tsc2/ cells (Figure 4B). The changes in Hif-
1 were mirrored by changes in the Glut1 glucose transporter,they were grown in low serum (Figure 1C). As previously shown
which is the product of a Hif target gene. These data suggest thatby others (Jaeschke et al., 2002), serum deprivation failed to
Hif-1 accumulation in Tsc2-null cells results from inappropriateblock S6 phosphorylation in Tsc2/ cells (Figure 1C). Interest-
activation of mTOR.ingly, the failure to downregulate S6 kinase activity was mirrored
by a failure to downregulate Hif-1. These results suggest that
Increased Hif transcriptional activity in Tsc2-null cellsthe mechanism whereby Tsc2 regulates Hif-1 is sensitive to
To evaluate the functional significance of Hif-1 elevation inserum and may involve mTOR. Northern blot analysis revealed
Tsc2-null cells, Northern blot analyses of Tsc2/ and Tsc2/that the increased accumulation of Hif-1 in Tsc2/ cells relative
MEFs were performed under standard growth conditions (10%to Tsc2/ cells was at least partly due to changes in Hif-1
serum) using probes for different Hif target genes includingmRNA levels (Figure 1D).
VEGF, which is involved in angiogenesis, PGK1 and Eno1, which
are involved in glucose metabolism, and the abovementionedWild-type Tsc2 inhibits Hif-1
To study further the functional relationship between Tsc2 and Glut1. While the expression of Eno1 was similar between the
two cell types, the expression of VEGF, Glut1, and PGK1 mRNAsHif, Tsc2/ MEFs were transfected with a mammalian expres-
sion vector encoding either wild-type TSC2 or a disease-associ- was elevated in Tsc2/ cells compared to controls (Figure 5A).
These differences were even more pronounced under low serumated TSC2 missense mutant (N1645K) along with a vector en-
coding enhanced green fluorescence protein. Successfully conditions, in keeping with the differences in Hif-1 protein
levels shown in Figure 1C (data not shown). These data suggesttransfected cells were collected by FACS, replated, and subse-
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Figure 2. Suppression of Hif-1 after restoration of
TSC function
A: Tsc2/ MEFs were transfected with plasmids
(10 or 16 g, as indicated) encoding wild-type
(“Wt”) or mutant (N1645K; “Mut”) TSC2, or the
empty vector (pcDNA3), as well as a plasmid
encoding enhanced green fluorescent protein
(EGFP). GFP-positive cells were isolated by FACS
and replated in media containing 0.05% serum.
Eighteen hours later, immunoblots were per-
formed with the indicated antibodies.
B: Immunoblots of untransfected Tsc2/ and
Tsc2/ MEFs grown in 0.1% serum performed un-
der the same experimental conditions as in A.
that the modest elevation in Hif-1 levels observed in Tsc2/ (Figure 1B), the accumulation of these transcripts following
cells under serum-rich conditions translates into increased ex- chronic exposure to hypoxia was more sustained in the Tsc2/
pression of at least a subset of Hif target genes. All four of these cells relative to controls. Hif-1 mRNA levels, in contrast to Hif-
mRNAs were induced by hypoxia, in keeping with their being 1 protein levels, were not altered by hypoxia in either Tsc2/
regulated by Hif (Figure 5B). As was observed for Hif protein or Tsc2/ cells (Figure 5B). The failure of Tsc2/ cells to down-
regulate Hif-1 protein levels, and its mRNA targets, with pro-
longed hypoxia must therefore reflect postranscriptional changes
in Hif-1 following TSC inactivation. Of note, the control of HIF
target genes in MEFs depends entirely on Hif-1 and not its
paralog, Hif2- (Park et al., 2003).
VEGF upregulation in Tsc2-null cells
VEGF is thought to be important for neoangiogenesis and tumor
development (Ferrara, 2002). Moreover, the induction of VEGF
mRNA in Tsc2-null cells appeared to be disproportionate to the
changes seen in other hypoxia-inducible mRNAs (Figure 5A).
To assess the significance of VEGF mRNA upregulation, we
evaluated VEGF protein levels in the conditioned media of
Tsc2/ and Tsc2/ MEFs. Since in serum-rich media the abun-
dance of secreted proteins (such as VEGF) relative to exogenous
proteins is very low, cells were grown in synthetic, serum-free
media. Conditioned media were concentrated by TCA precipita-
tion, normalized for protein concentration, and immunoblotted
with an anti-VEGF antibody. As shown in Figure 5C, the levels
of VEGF protein were significantly higher in Tsc2-null cells than
in controls.
These results were corroborated by performing VEGF ELISAs
on conditioned media derived from comparable numbers of
Tsc2/ and Tsc2/ cells grown under standard conditions (Fig-
ure 5D). To control for any global differences in metabolic rates
or rates of cell proliferation, VEGF levels were normalized within
each sample to intracellular protein concentration. IntracellularFigure 3. Inhibition of TSC2 is sufficient to enhance HIF-1 accumulation
protein levels were typically higher in the Tsc2/ cells comparedA: Anti-TSC2 and anti-tubulin immunoblot analysis of U2OS osteosarcoma
cells 48 hr after transfection with siRNA directed against EGLN1, against to controls, but were usually within a factor of 2 (data not shown).
TSC2 (sequence “a” or sequence “b”), or scrambled control (“Sc”). Hence, even after normalization, VEGF protein levels in the con-
B: Anti-HIF-1 and anti-tubulin immunoblot analysis 6 days after transfection
ditioned media of Tsc2/ cells were markedly elevated com-with siRNA used in A. Cells were placed in media containing 10% or 0%
serum 3 days after transfection as indicated. pared to controls (see also Figure 6B).
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Hif-1 levels (Figure 4B) or VEGF levels (Figure 6B) in Tsc2/
cells. These data indicate that loss of Tsc2 results in the inappro-
priate activation of mTOR, mTOR-mediated upregulation of Hif,
and the upregulation of VEGF. Importantly, these data also sug-
gest the existence of an mTOR-independent pathway leading
to VEGF upregulation in Tsc2/ cells.
Trichostatin A is a potent inhibitor of VEGF
To begin to explore the mTOR-independent pathway, we treated
Tsc2/ cells with drugs that inhibit signal transduction pathways
known to regulate VEGF (Table 1). Among these were inhibitors
of PI3K and Ras pathways, Src, as well as inhibitors of various
protein kinases, histone deacetylase, and nitric oxide synthase
(NOS) (Table 1). Since many of these drugs can affect cell prolif-
eration, VEGF levels were normalized to intracellular protein
concentrations. Of the drugs screened, only Trichostatin A (TSA)
consistently downregulated VEGF by50% (Figure 7). A mean-
ingful analysis of the effects of TSA on Tsc2/ cells was not
possible because they produce very low levels of VEGF under
basal conditions. Since TSA blocks protein deacetylation, we
examined protein acetylation patterns in Tsc2/ and Tsc2/
cell lysates using an antibody directed against acetylated lysine
residues. Preliminary results using this approach have not re-
vealed a difference in the global pattern of protein acetylation
between these two cell types (data not shown). Finally, the
treatment of Tsc2/ cells with both Rapamycin and TSA simulta-
neously did not have additive effects, compared to treatment
with each drug individually (data not shown), suggesting that the
pathways regulated by TSA and Rapamycin are not completely
independent of each other.
Discussion
Tsc2-null cells have higher levels of Hif-1 mRNA and protein
than Tsc2/ cells. Reintroduction of wild-type TSC2 into Tsc2-
null MEFs downregulates Hif-1. Conversely, downregulation
of TSC2 with siRNA upregulates Hif-1. These results indicateFigure 4. Rapamycin inhibits Hif-1 accumlation in Tsc2/ cells
that TSC2 is an important regulator of HIF. The increase in Hif-A and B: Immunoblot analysis with the indicated antibodies of Tsc2/ and
Tsc2/ cells grown in presence (“”) or absence (“”) of 25 nM Rapamycin 1 levels in Tsc2-null cells appears to be functionally important
for 36 hr. In B, cells were grown in high (10%) or low (0.1%) serum for 40 hr as it is accompanied by increased expression of Hif target
as indicated. genes.
Our results are consistent with a recent study by Liu and
coworkers who found that Hif-2 was elevated in renal carci-
noma cell lines derived from tumors arising in the Eker rat (LiuRapamycin downregulates VEGF secretion
et al., 2003). However, their study did not allow any conclusionsin Tsc2-null cells
regarding the role of Tsc2 in this process since Hif-2 wasTo evaluate the contribution of mTOR to VEGF upregulation in
similarly elevated in chemically transformed Tsc2/ rat kidneyTsc2-null cells, we repeated these experiments in the presence
cell lines used as controls (Liu et al., 2003). One interestingor absence of Rapamycin. Treatment of Tsc2/ cells with Rapa-
possibility suggested by these authors was that Hif-2 elevationmycin under conditions that blocked S6 phosphorylation (Figure
in the Tsc2/ cell lines reflected mutations at other loci that4A) and normalized Hif-1 levels (Figure 4B) led to diminished
impinge upon Hif regulation.VEGF secretion, albeit to levels that were still markedly elevated
Both the Tsc2/ and Tsc2/ MEFs used in our studiescompared to Tsc2/ cells (Figure 6A). The effect of Rapamycin
lacked p53, and both p53 as well as its downstream targetwas even less pronounced if VEGF levels were normalized for
MDM2 have been implicated in HIF regulation (Carmeliet ettotal intracellular protein concentration in an attempt to correct
al., 1998; Ravi et al., 2000). Thus, our MEF data might reflectfor Rapamycin’s known inhibitory effect on global protein trans-
a genetic interaction between Tsc2 and p53. On the other hand,lation (Figure 6B). Treatment with Rapamycin using 10-fold
downregulation of TSC2 in p53/ U2OS osteosarcoma cellshigher concentrations did not decrease VEGF levels further (data
also led to the elevation of HIF. Nonetheless, it remains possiblenot shown). Likewise, VEGF continued to be overproduced by
that HIF dysregulation following TSC inactivation requires a sec-Tsc2/ cells that were pretreated with Rapamycin for 24 hr
ond “hit” such as p53 loss.prior to media replacement with fresh, Rapamycin-containing
media (data not shown). In contrast, Rapamycin did not affect Serum deprivation results in the downregulation of Hif-1
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Figure 5. Activation of HIF target genes in Tsc2/
cells
A and B: Northern blot analysis of Tsc2/ and
Tsc2/ MEFs with the indicated probes. In B, cells
were exposed to 1% oxygen for the duration indi-
cated prior to analysis.
C: Similar numbers of Tsc2/ and Tsc2/ MEFs
were plated and maintained in synthetic, serum-
free media. Thirty-six hours later, conditioned me-
dia were immunoblotted for VEGF (after TCA
precipitation and normalization for total protein).
D: Similar numbers of Tsc2/ and Tsc2/ MEFs
were plated and maintained in serum-rich (10%
serum) media for 24 hr. VEGF levels were ana-
lyzed by ELISA. Error bars equal one standard
deviation (n  3).
mRNA and protein levels in Tsc2/ cells but not in Tsc2/ events, including activation of AKT (Treins et al., 2002; Zhong
et al., 2000; Zundel et al., 2000), inactivation of PTEN (Jiang etcells. Hence, growth factor deprivation leads to Hif-1 downreg-
ulation through a mechanism that requires Tsc2. There is prece- al., 2001), HER2 overexpression (Laughner et al., 2001), and the
BCR-ABL (Mayerhofer et al., 2002) also upregulate HIF throughdence for growth factor signals impinging upon Hif-1 mRNA
accumulation (Jiang et al., 1997). Interestingly, the inappropriate mTOR. Based on our findings, it is likely that TSC1, which
negatively regulates mTOR in complex with TSC2, also regulateselevation of Hif-1 protein in Tsc2-null cells can be corrected
by Rapamycin. These data are consistent with a model whereby HIF, but this remains to be proven.
The induction of Hif-1 protein and Hif-responsive tran-loss of TSC2 results in activation of mTOR, which in turn upregu-
lates HIF-1. It seems fitting that mTOR, which functions in an scripts by hypoxia is attenuated following prolonged exposure
to low oxygen, presumably due to a feedback mechanism. Thisinsulin-responsive pathway that regulates cell growth, would
also activate HIF. In this way, mTOR would couple increased attenuation, which requires TSC2, appears to be postranscrip-
tional as it is not accompanied by changes in Hif-1 mRNAprotein translation and cell growth with enhanced glucose up-
take, energy generation, and development of an adequate blood levels. Conceivably, mTOR phosphorylates HIF-1 or one of its
upstream regulators such as pVHL or EGLN. Interestingly, thesupply. Notably, upregulation of HIF by mTOR appears to be
a common mechanism in tumorigenesis. Multiple oncogenic primary sequences of both HIF-1 and EGLN1 reveal potential
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Table 1. List of drugs used in screen for VEGF inhibitors in Tsc2-null MEFs
Drug Target Conc. Reference
LY294002 PI3K 20 M (Suzuma et al., 2002)
Wortmannin PI3K 0.1 M (Suzuma et al., 2002)
PD098059 MEK1 100 M (Pedram et al., 1998),
(Milanini et al., 1998)
U0126 MEK1/2 50 M (Stiehl et al., 2002)
SB203580 P38 30 M (Yamamoto et al., 2001)
PD169316 P38 10 M (Yamamoto et al., 2001)
SB202190 P38 0.35 M (Pages et al., 2000)
SP600125 JNK 10 M (Wang et al., 2002)
FTI277 Farnesyl 10 M (Maity et al., 2000)
transferase
AG1478 EGFR 10 M (Maity et al., 2000)
H89 PKA 1 M (Ghosh et al., 2001)
Calphostin C PKC 0.1 M (Friedlander et al., 1995)
Go6983 PKC 0.1 M (Fedorov et al., 2002)
Genistein SRC 50 M (Suzuma et al., 2002)
Herbymicin A PTK/SRC 3.4 M (Gruden et al., 1997)
PP2 SRC 50 M (Fredriksson et al., 2000)
H7 S/T Kinase 50 M (Park et al., 2001)
LY83583 Guanylate 1 M (Chin et al., 1997)
cyclase
TSA HDAC 100 ng/ml (Kim et al., 2001)
L-NAME NOS 3 mM (Gavin et al., 2000)
tween TSC and VHL disease. The importance of HIF with respect
to VHL-associated tumor development is underscored by the
fact that tumor suppression by pVHL can be overridden by HIF
variants that do not bind to pVHL (Kondo et al., 2002; Maranchie
et al., 2002).
It is noteworthy that kidney cancer is a prominent feature
of both VHL disease and the Eker (Tsc2/) rat. The majority of
sporadic clear cell RCC also harbor (somatic) VHL mutations
and, accordingly, overproduce HIF and its downstream targets
(Wiesener et al., 2001). Interestingly, TSC patients are also at
an increased risk for clear cell RCC (Walker, 1998), and when
Figure 6. Effects of Rapamycin on VEGF secretion in Tsc2-null cells tumors arise in this setting, they typically are VHL/ (Parry
A and B: Similar numbers of Tsc2/ and Tsc2/ MEFs were plated and et al., 2001). One explanation would be that dysregulation of
maintained in serum-rich (10% serum) media in the presence () or absence HIF following loss of TSC reduces the selection pressure to
() of Rapamycin (25 nM). Thirty-six hours later, conditioned media were eliminate pVHL.
analyzed by anti-VEGF ELISA and cell extracts were prepared as in Figure
A number of HIF targets have been implicated in tumorigene-4A. VEGF values were (B) or were not (A) normalized to total cellular protein.
sis. HIF induces multiple changes in cellular glucose uptakeError bars equal one standard deviation (n  3).
and metabolism that allow for sustained energy generation in
a hypoxia environment (“Warburg Effect”) (Seagroves et al.,
2001). In addition, HIF directs the production of autocrine growth
mTOR phosphorylation sites (Schalm and Blenis, 2002). More- factors (for example, TGF) that act as mitogens, as well as
over, the region of HIF-1 called the ODD domain (oxygen- angiogenic factors (for example, VEGF and PDGF B). The impor-
dependent degradation domain), which contains the HIF-1 pro- tance of HIF with respect to tumorigenesis is underscored by
lyl hydroxylation/pVHL binding site, is also sufficient for HIF-1’s the finding that genetic disruption of HIF in most (but not all)
Rapamycin sensitivity in the setting of PI3K pathway activation models tested to date impedes tumor formation in vivo (Pugh
and Ratcliffe, 2003).(Hudson et al., 2002). That mTOR signals to HIF-1 through
EGLN1 is supported by our observation that EGLN1 is required Upregulation of VEGF following TSC inactivation is striking
and seemingly disproportionate to other HIF targets. Moreover,for HIF-1 downregulation by low serum (Figure 3B).
Since a patient-derived TSC2 missense mutant was im- treatment of Tsc2/ cells with Rapamycin at concentrations
that are sufficient to inhibit mTOR and normalize Hif-1 produc-paired with respect to downregulation of Hif-1, it appears that
regulation of HIF by TSC2 is important for its tumor suppressor tion (as well as the canonical Hif target Glut1) does not com-
pletely normalize VEGF. The simplest interpretation of thesefunction. Inappropriate activation of HIF contributes to tumor
formation in other settings including tumors, such as renal cell data is that TSC regulates VEGF through mTOR-dependent
and -independent pathways. VEGF regulation is complex andcarcinomas and hemangioblastomas, that are linked to inactiva-
tion of the VHL gene (Maher and Kaelin, 1997). Indeed, HIF involves both transcriptional and posttranscriptional mecha-
nisms (Robinson and Stringer, 2001). Recent studies are consis-dysregulation may underlie the partial phenotypic overlap be-
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Figure 7. Screen for drugs that downregulate
VEGF in Tsc2-null fibroblasts (see also Table 1)
Tsc2/ MEFs were plated and maintained in stan-
dard media with 10% serum. Drugs were added
to fresh media containing 10% serum for 36 hr
prior to analysis of VEGF levels by ELISA. In paral-
lel, Tsc2/ and Tsc2/ cells were treated with
DMSO (“D”). Shown are VEGF values normalized
to total cellular protein. Error bars equal one stan-
dard deviation (n  3).
tent with the idea that regulation of the VEGF promoter by defective cells would likewise be particularly sensitive to Rapa-
mycin. Finally, histone deacetylase inhibitors are also beingthe PI3K pathway is complex and involves HIF-dependent and
tested in man and, based on our studies, might be useful ad--independent pathways (Pore et al., 2003).
juncts in this setting.Earlier studies indicated that histone deacetylase inhibitors
block VEGF overproduction in certain settings (Kim et al., 2001).
Experimental proceduresIn keeping with this, we found that VEGF overproduction by
Tsc2/ cells is very sensitive to TSA. How TSA affects VEGF MEF culture
production is not yet clear. In one study, downregulation of Tsc2/; p53/ and Tsc2/; p53/ MEFs between passages 6 and 8 were
VEGF with TSA was correlated with increased production of obtained from D.J. Kwiatkowski and grown in DMEM supplemented with
10% heat inactivated fetal bovine serum (or lower percentages as indicated)pVHL and p53 (Kim et al., 2001). In any event, our findings
and in a 10% humidified CO2 incubator. Cells were analyzed up to passagesuggest that TSC inactivation ultimately impacts upon chroma-
12. Where indicated, Deferoxamine (DFO) (Sigma) was added to the mediatin structure. Notably, a link between histone acetylation and from a freshly prepared 100 mM stock solution in sterile water to a final 200
TSC2 had been previously suggested. TSC2 was found to bind M concentration. Where indicated, Rapamycin (Calbiochem) was added
to several nuclear receptors in vitro and to affect their transcrip- to the media from a 25 M stock solution in methanol to a final concentration
of 25 nM. All other drugs were obtained from Calbiochem and were dissolvedtional transactivation activities in cells (Henry et al., 1998). While
in water or DMSO as recommended by the manufacturer.TSC2 is thought to be a cytosolic protein (Wienecke et al., 1996),
it is possible that a small fraction localizes to the nucleus where
Protein extraction and immunoblot analysis
it may affect transcription. Adherent cells were washed with PBS and lysed in 50 mM Tris-HCl (pH
Rapamycin has been shown to decrease tumor growth and 7.4), 250 mM NaCl, and 0.5% NP-40 supplemented with protease inhibitors
(Complete Mini, ROCHE) for 30 min at 4C. Protein concentration was deter-angiogenesis in vivo (Guba et al., 2002). PTEN loss, which leads
mined by the Bradford Method (Bio-Rad). For each gel, comparable amountsto activation of the PI3K pathway and mTOR, sensitizes cells
of protein were loaded per lane, electrophoretically resolved, and wet trans-to the antiproliferative effects of Rapamycin in vivo (Neshat et al.,
ferred onto a 0.45 m Nitrocellulose membrane (Bio-Rad). Membranes were
2001; Podsypanina et al., 2001), possibly due to a phenomenon blocked in TBS with 0.1% Tween and 5% nonfat dry milk and probed with
referred to as “oncogene addiction” (Mills et al., 2001; Weinstein, the indicated primary antibody (polyclonal HIF-1 [gift of J. Pouyssegur]
[Richard et al., 1999], polyclonal TSC2 [Santa Cruz C-20], polyclonal Phos-2002). Based on this observation, one might predict that TSC-
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pho-S6 S235/236 [Cell Signaling], polyclonal S6 [Cell Signaling], monoclonal were estimated using the Bradford Method (Pierce). Immunoblot analysis
was performed as described above using 200 g protein/lane.Tubulin- [Sigma, clone B-5-1-2], or polyclonal hVEGF [R&D AF-493-NA]).
Bound antibody was detected with an appropriate HRP-conjugated second-
ary antibody (Pierce) and chemiluminescence (Pierce). VEGF ELISA
Cells were seeded in 12 well plates (100,000 cells per well). Three indepen-
dent wells were used for each set of experimental conditions. Once the cellsTransfection and FACS sorting
were attached, the media were changed to DMEM with 10% serum andTsc2-null MEFs (90% confluent) were transfected with pcDNA3-TSC2,
drugs were added as indicated. Twenty-four to thirty-six hours later, VEGFpcDNA3-TSC2 (N1645K) (Inoki et al., 2002), or the backbone vector, along
ELISA (R&D Systems) were performed (50 l media/well) according to manu-with enhanced green fluorescence protein (EGFP) expression vector, using
facturer’s instructions with a Wallac Victor 2 (PerkinElmer). Where stated,Lipofectamine Plus (Invitrogen). Eighteen to twenty-four hours later, GFP
VEGF protein levels were divided by the intracellular protein concentrationsexpression was confirmed under UV light using an ECLIPSE TE 200 micro-
within each sample for normalization.scope (Nikon). Cells were trypsinized, resuspended in a solution containing
66% trypsin in PBS and 15 mM EDTA, and sorted at a rate of 8,000–10,000
Acknowledgmentsevents/s using an EPICS ALTRA FACS machine (Beckman Coulter) under
sterile conditions. Cells with fluorescence intensity that was 1 log above
We thank H. Onda and D.J. Kwiatkowski for p53/;Tsc2/ anduntransfected controls were collected and aliquoted to 12 well plates
p53/;Tsc2/ MEFs; J. Pouyssegur for anti-HIF-1 antibody; K. Inoki for a(300,000 	 5% cells/well). Sorting resulted in an enrichment of EGFP-posi-
mutant TSC2 expression vector and sequence information on Tsc2 siRNA;tive cells from 20%–30% presorted to 95% after sorting (data not shown).
J. Daley and S. Lazo-Kallanian in the FACS-Cell Sorter facility, and membersAfter a few hours, cells were washed with PBS and media replaced with
of the Kaelin Laboratory for useful discussions. W.G.K. is a Howard HughesDMEM containing 0.05% serum. Eighteen hours later, cell lysates were
Medical Institute Investigator. This work was supported by the NIH and byprepared.
the Murray Foundation.
RNAi experiments
U2OS osteosarcoma cells (30%–50% confluence) were grown in 6 well
plates. Prior to transfection, cells were washed with PBS and media replaced
Received: June 2, 2003with 800 l of OPTI-MEM I (Invitrogen). In parallel, 4 l of Oligofectamine
Revised: July 8, 2003(Invitrogen) was combined with 11 l of OPTI-MEM I and incubated at room
temperature for 10 min. 1.5 g of the indicated duplex siRNA oligonucleotide Published: August 25, 2003
(Dharmacon) was diluted into 180 l of OPTI-MEM I, added to the Oligofec-
Referencestamine/OPTI-MEM I mixture, and incubated at room temperature for 20 min.
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by low oxygen tension. J. Biol. Chem. 277, 13508–13517.or replated. Twenty-four hours later, cells were switched to media with either
10% or 0% serum and harvested 3 days later for Western blot analysis.
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